Triangle firm's coronavirus treatment shows improvement in patients

A Triangle drugmaker pushing the development of a potential Covid-19 treatment has the first analysis of its drug in a peer-reviewed journal – and the results are good. Results from the first patients treated with Raleigh's RedHill (Nasdaq: RDHL) drug, opaganib, were published in medRxiv. The analysis concerns patients treated in Isreal – which approved the drug for compassionate use in the early days of the pandemic. According to the study, seven patents with "severe Covid-19" who required…